HC Wainwright Cuts Protalix BioTherapeutics (NYSE:PLX) Price Target to $12.00

Protalix BioTherapeutics (NYSE:PLX) had its price objective reduced by HC Wainwright from $15.00 to $12.00 in a research note published on Friday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.05 EPS, Q3 2026 earnings at $0.05 EPS and Q4 2026 earnings at $0.06 EPS.

Protalix BioTherapeutics Stock Performance

NYSE PLX opened at $1.75 on Friday. The stock has a 50 day moving average price of $2.18 and a 200-day moving average price of $1.78. Protalix BioTherapeutics has a one year low of $1.32 and a one year high of $3.10. The company has a market capitalization of $140.74 million, a P/E ratio of -13.46 and a beta of -0.18.

Institutional Trading of Protalix BioTherapeutics

A number of large investors have recently made changes to their positions in the business. Geode Capital Management LLC purchased a new stake in shares of Protalix BioTherapeutics during the 2nd quarter valued at about $1,223,000. Stratos Wealth Partners LTD. grew its position in Protalix BioTherapeutics by 42.9% in the third quarter. Stratos Wealth Partners LTD. now owns 500,000 shares of the company’s stock worth $1,110,000 after acquiring an additional 150,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Protalix BioTherapeutics by 2.8% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 496,216 shares of the company’s stock worth $734,000 after acquiring an additional 13,341 shares during the last quarter. Jane Street Group LLC increased its stake in Protalix BioTherapeutics by 159.0% during the first quarter. Jane Street Group LLC now owns 294,318 shares of the company’s stock worth $753,000 after acquiring an additional 180,702 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Protalix BioTherapeutics by 482.3% during the first quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company’s stock valued at $741,000 after purchasing an additional 239,751 shares during the period. 16.53% of the stock is currently owned by institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.